Tuesday, 20 Mar 2018

You are here

TNF Inhibitor Therapy and the Risk of Anterior Uveitis Recurrence

The TNF inhibitor drug development trials have indirectly taught us that monoclonal antibody based TNFi was capable of retarding the recurrence of anterior uveitis (AU) in patients with ankylosing spondylitis (AS).

This issue has been revisited by Swedish investigators who studied the ability of adalimumab (ADA), etanercept (ETN) and infliximab (IFX) on AU recurrence in AS patients using patients from the Swedish Rheumatology Quality Register starting their first TNFi between January 2003 to December 2010. 

The study included 1365 patients with AS.

Compared with pretreatment rates, reduced rates for AU rates were seen with ADA and IFX, while an increased AU rate was seen for ETN.

The adjusted HRs for developing AU were significantly higher for ETN versus ADA (HR: 3.86) and ETN versus IFX (HR: 1.99), while the HR for IFX versus ADA was not statistically significant.

These data confirm earlier observational studies showing the efficacy of ADA and IFX in AU. However, this study suggests little or no protection when using ETN. Suggesting mechanistic differences between antibody and receptor based therapies are clinically important in this particular extraspinal manifestation of AS.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Bone Marrow Edema Found in SI Joint of Athletes

New research shows that young elite athletes will not commonly manifest bone marrow edema in the SI joint following activity.

A study in Arthritis & Rheumatology  assessed for MRI findings commonly seen in patients with axial spondyloarthropathy (axial Spa). (Citation source: https://buff.ly/2DrlCgB)

Recurrent Uveitis Increases the Risk of Ankylosing Spondylitis

Arthritis Research and Therapy reports on the epidemiologic association between recurrent anterior uveitis and ankylosing spondylitis (AS) noting that as the number of uveitis episodes increases, so does the incidence of AS.

Opioid Use in Ankylosing Spondylitis

A prospective study has shown that ankylosing spondylitis (AS) patients often require narcotic analgesics to manage pain unresponsive to antiinflammatory therapies.

AS patients (n=706) were serially assessed (every 6 months) and outcome measures were collected, including disease activity and functional measures (BASDAI, BASFI), along with radiographic outcomes.  Investigators specifically looked at opioid usage.

Cimzia Limits Xray Progression in Axial Spondyloarthritis

The RAPID-axSpA study of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients showed that certolizumab pegol (CZP) treatment yielded rapid clinical improvement with limited radiographic progression and MRI inflammation at the sacroiliiac (SI) joint over 4 years.

Apremilast’s Rapid Onset in Psoriatic Arthritis

Monotherapy with apremilast (Otezla) among patients with psoriatic arthritis who were biologic-naive was significantly more effective than placebo as early as week 2 in a phase IIIb study.